WO2006031467A3 - Isolated lineage negative hematopoietic stem cells and methods of treatment therewith - Google Patents

Isolated lineage negative hematopoietic stem cells and methods of treatment therewith Download PDF

Info

Publication number
WO2006031467A3
WO2006031467A3 PCT/US2005/031304 US2005031304W WO2006031467A3 WO 2006031467 A3 WO2006031467 A3 WO 2006031467A3 US 2005031304 W US2005031304 W US 2005031304W WO 2006031467 A3 WO2006031467 A3 WO 2006031467A3
Authority
WO
WIPO (PCT)
Prior art keywords
isolated
monocytes
lin
lineage
hscs
Prior art date
Application number
PCT/US2005/031304
Other languages
French (fr)
Other versions
WO2006031467A2 (en
WO2006031467A9 (en
Inventor
Martin Friedlander
Atsushi Otani
Silva Karen Da
Stacey Hanekamp Moreno
Original Assignee
Scripps Research Inst
Martin Friedlander
Atsushi Otani
Silva Karen Da
Stacey Hanekamp Moreno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/933,634 external-priority patent/US20050129665A1/en
Application filed by Scripps Research Inst, Martin Friedlander, Atsushi Otani, Silva Karen Da, Stacey Hanekamp Moreno filed Critical Scripps Research Inst
Priority to CN2005800379820A priority Critical patent/CN101052305B/en
Priority to AU2005285246A priority patent/AU2005285246B2/en
Priority to KR1020077007667A priority patent/KR101309500B1/en
Priority to MX2007002639A priority patent/MX2007002639A/en
Priority to CA002579292A priority patent/CA2579292A1/en
Priority to JP2007530394A priority patent/JP2008512376A/en
Priority to EP05814042A priority patent/EP1802199A4/en
Publication of WO2006031467A2 publication Critical patent/WO2006031467A2/en
Publication of WO2006031467A9 publication Critical patent/WO2006031467A9/en
Publication of WO2006031467A3 publication Critical patent/WO2006031467A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell population (Lin HSCs) contain endothelial progenitor cells (ECPs) capable of rescuing retinal blood vessels and neuronal networks in the eye. Preferably at least about 20% of the cells in the isolated Lin HSCs express the cell surface antigen CD31. The isolated Lin HSC populations are useful for treatment of ocular vascular diseases and to ameliorate cone cell degeneration in the retina. In a preferred embodiment, the Lin HSCs are isolated by extracting bone marrow from an adult mammal; separating a plurality of monocytes from the bone marrow; labeling the monocytes with biotin-conjugated lineage panel antibodies to one or more lineage surface antigens; removing of monocytes that are positive for the lineage surface antigens from the plurality of monocytes, and recovering a Lin HSCs population containing EPCs. The isolated Lin HSCs also can be transfected with therapeutically useful genes. The treatment may be enhanced by stimulating proliferation of activated astrocytes in the retina using a laser.
PCT/US2005/031304 2002-07-25 2005-09-02 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith WO2006031467A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN2005800379820A CN101052305B (en) 2004-09-03 2005-09-02 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
AU2005285246A AU2005285246B2 (en) 2004-09-03 2005-09-02 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
KR1020077007667A KR101309500B1 (en) 2004-09-03 2005-09-02 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
MX2007002639A MX2007002639A (en) 2004-09-03 2005-09-02 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith.
CA002579292A CA2579292A1 (en) 2004-09-03 2005-09-02 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
JP2007530394A JP2008512376A (en) 2004-09-03 2005-09-02 Isolated lineage negative hematopoietic stem cells and therapeutic method using the same
EP05814042A EP1802199A4 (en) 2004-09-03 2005-09-02 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39852202P 2002-07-25 2002-07-25
US46705103P 2003-05-02 2003-05-02
US10/933,634 US20050129665A1 (en) 2002-07-25 2004-09-03 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US10/933,634 2004-09-03

Publications (3)

Publication Number Publication Date
WO2006031467A2 WO2006031467A2 (en) 2006-03-23
WO2006031467A9 WO2006031467A9 (en) 2006-06-01
WO2006031467A3 true WO2006031467A3 (en) 2006-11-02

Family

ID=46205697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031304 WO2006031467A2 (en) 2002-07-25 2005-09-02 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith

Country Status (1)

Country Link
WO (1) WO2006031467A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1935976T3 (en) * 2005-02-24 2012-07-31 Scripps Research Inst Transfected myeloid-like cells for the treatment of retinopathy of prematurity and related diseases
AU2006229687B2 (en) * 2005-02-24 2011-08-11 The Scripps Research Institute Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
US8747905B2 (en) * 2006-10-27 2014-06-10 Emory University Therapeutic use of CD31 expressing cells
AU2010216374A1 (en) * 2009-02-20 2011-08-18 The Scripps Research Institute Isolated monocyte populations and related therapeutic applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010959A2 (en) * 2002-07-25 2004-02-05 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010959A2 (en) * 2002-07-25 2004-02-05 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1802199A4 *
SMITH L.E.H.: "Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa", J. CLIN. INVEST., vol. 114, no. 6, September 2004 (2004-09-01), pages 755 - 757, XP003001779 *

Also Published As

Publication number Publication date
WO2006031467A2 (en) 2006-03-23
WO2006031467A9 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
WO2004098499A3 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
Magatti et al. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes
Cao et al. Mesenchymal stem cells and adaptive immune responses
CN104487568B (en) The mesenchymal stem cells of derived from human embryonic stem, method and its application
JP2014507389A (en) Treatment of spinal cord injury and traumatic brain injury using amnion-derived adherent cells
JP2014507390A (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells
Marchetti et al. Stemming vision loss with stem cells
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2006091895A3 (en) Method for the treatment of retinopathy of prematurity and related retinopathic diseases
US8524283B2 (en) T cell immunomodulation by placenta cell preparations
US20220110979A1 (en) Fibroblast regenerative cells
MX2019002288A (en) Cell suspension for use in the treatment of lower extremity peripheral artery disease.
WO2006031467A3 (en) Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
DE69634982D1 (en) PROCESS FOR INCREASING HEMATOPOIETIC CELLS
Rocco et al. Regulatory T cells: the ultimate HIV reservoir?
AR018489A1 (en) USE OF A GENETICALLY PERFORMED CELL THAT INCLUDES DNA CODIFYING A TRANSMEMBRANE AND PROTEIN LYMPHOCATE ACTIVATION GENE PROTEIN 3 (LAG-3) FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT TO INDICATE THE PROTECTION OF MISCELLENT RETIREMENT AND USE OF THE SAME
WO2006104609A3 (en) Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
EP1624758A4 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
AU2704197A (en) Immortalized retinal cell lines and their applications
JP2006166918A5 (en)
RU2017123184A (en) TREATMENT OF EYE PATHOLOGIES USING PRECEDENT CELLS
WO2003029432A3 (en) Human mesenchymal progenitor cell
Gratzer et al. A new decellularized dermal matrix: superior properties and in-vivo performance when compared with the leading commercial product
Xu et al. Immune Response of Mesenchymal Stem Cells in Repairing Bone Injury

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/29-29/29, DRAWINGS, REPLACED BY NEW PAGES 1/29-29/29; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002639

Country of ref document: MX

Ref document number: 2007530394

Country of ref document: JP

Ref document number: 2579292

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005285246

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005285246

Country of ref document: AU

Date of ref document: 20050902

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005285246

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005814042

Country of ref document: EP

Ref document number: 1020077007667

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580037982.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005814042

Country of ref document: EP